» Articles » PMID: 25598171

Prolonged Hypogonadism in Males Following Withdrawal from Anabolic-androgenic Steroids: an Under-recognized Problem

Overview
Journal Addiction
Specialty Psychiatry
Date 2015 Jan 20
PMID 25598171
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To assess the frequency and severity of hypogonadal symptoms in male long-term anabolic-androgenic steroid (AAS) misusers who have discontinued AAS use.

Design: Cross-sectional, naturalistic.

Setting: Out-patient facility.

Participants: Twenty-four male former long-term AAS users and 36 non-AAS-using weightlifters, recruited by advertisement in Massachusetts, USA. Five of the former users were currently receiving treatment with physiological testosterone replacement, leaving 19 untreated users for the numerical comparisons below.

Measurements: The Structured Clinical Interview for DSM-IV, questions regarding history of AAS use, physical examination, serum hormone determinations and the International Index of Erectile Function (IIEF).

Findings: Compared with the 36 non-AAS-using weightlifters, the 19 untreated former AAS users displayed significantly smaller testicular volumes [estimated difference, 95% confidence interval (CI) = 2.3 (0.1, 4.5) ml; P = 0.042] and lower serum testosterone levels [estimated difference: 95% CI = 131 (25, 227) dl; P = 0.009], with five users showing testosterone levels below 200 ng/dl despite abstinence from AAS for 3-26 months. Untreated former users also displayed significantly lower scores on the IIEF sexual desire subscale [estimated difference: 95% CI = 2.4 (1.3, 3.4) points on a 10-point scale; P < 0.001]. In the overall group of 24 treated plus untreated former users, seven (29%) had experienced major depressive episodes during AAS withdrawal; four of these had not experienced major depressive episodes at any other time. Two men (8%) had failed to regain normal libidinal or erectile function despite adequate replacement testosterone treatment.

Conclusions: Among long-term anabolic-androgenic steroid misusers, anabolic-androgenic steroid-withdrawal hypogonadism appears to be common, frequently prolonged and associated with substantial morbidity.

Citing Articles

The sexual impact of androgenic anabolic steroid abuse an understudied phenomena.

Akula K, McBeth L, Hofer M Int J Impot Res. 2024; 37(2):114-115.

PMID: 38594389 DOI: 10.1038/s41443-024-00879-6.


Use of Anabolic-Androgenic Steroids and Male Fertility: A Systematic Review and Meta-analysis.

Mulawkar P, Maheshwari P, Gauhar V, Agrawal S, Mohammed T, Singh A J Hum Reprod Sci. 2024; 16(4):268-285.

PMID: 38322636 PMC: 10841926. DOI: 10.4103/jhrs.jhrs_90_23.


Sleep pathology and use of anabolic androgen steroids among male weightlifters in Norway.

Klonteig S, Scarth M, Bjornebekk A BMC Psychiatry. 2024; 24(1):62.

PMID: 38254047 PMC: 10804719. DOI: 10.1186/s12888-024-05516-6.


The use of post-cycle therapy is associated with reduced withdrawal symptoms from anabolic-androgenic steroid use: a survey of 470 men.

Grant B, Kean J, Vali N, Campbell J, Maden L, Bijral P Subst Abuse Treat Prev Policy. 2023; 18(1):66.

PMID: 37951896 PMC: 10640727. DOI: 10.1186/s13011-023-00573-8.


Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review.

Solanki P, Eu B, Smith J, Allan C, Lee K Endocr Connect. 2023; 12(12).

PMID: 37855241 PMC: 10620455. DOI: 10.1530/EC-23-0358.


References
1.
Lloyd F, Powell P, Murdoch A . Anabolic steroid abuse by body builders and male subfertility. BMJ. 1996; 313(7049):100-1. PMC: 2351471. DOI: 10.1136/bmj.313.7049.100. View

2.
Brower K, Blow F, Eliopulos G, Beresford T . Anabolic androgenic steroids and suicide. Am J Psychiatry. 1989; 146(8):1075. DOI: 10.1176/ajp.146.8.1075a. View

3.
Boyadjiev N, Georgieva K, Massaldjieva R, Gueorguiev S . Reversible hypogonadism and azoospermia as a result of anabolic-androgenic steroid use in a bodybuilder with personality disorder. A case report. J Sports Med Phys Fitness. 2000; 40(3):271-4. View

4.
Jarow J, Lipshultz L . Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med. 1990; 18(4):429-31. DOI: 10.1177/036354659001800417. View

5.
Menon D . Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril. 2003; 79 Suppl 3:1659-61. DOI: 10.1016/s0015-0282(03)00365-0. View